UnknownNot Applicable

JAK-STAT Signaling Pathway in Pyoderma Gangrenosum

120 participantsStarted 2022-05-01

Plain-language summary

The investigators hypothese that Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway play a key role in pathophysiology of pyoderma gangrenosum (PG). In this study JAK/STAT signaling pathway will be investigated in the skin biopsies of PG patients

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pyoderma gangrenosum diagnosed with skin biopsy * Psoriasis diagnosed with skin biopsy * Hidradenitis suppurativa diagnosed with skin biopsy * Skin biopsy in healthy subjects Exclusion Criteria: \- This is a case-based study and there is no exclusion criteria

What they're measuring

Expression of JAK-STAT pathway

Timeframe: 15 years

Trial details

NCT IDNCT04792957

SponsorDokuz Eylul University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-07-31

Contact for this trial

Ismail Sari, M.Sc

+902324122222 ismailsari35@gmail.com

View on ClinicalTrials.gov More Pyoderma Gangrenosum trials